Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CALML3 | P27482 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170757 | 1.00 | F10 (0.46) | F10HTTCALML3GAAALDH1A1 | |
| SCHEMBL590436 | 1.00 | F10 (0.46) | F10HTTCALML3GAAALDH1A1 | |
| SCHEMBL1712464 | 0.91 | GRM2 (0.41) | F10HTTCALML3GAAGRM2 | |
| SCHEMBL591467 | 0.91 | GRM2 (0.41) | F10HTTCALML3GAAGRM2 | |
| SCHEMBL1712026 | 0.91 | GRM2 (0.41) | F10HTTCALML3GAAGRM2 | |
| SCHEMBL2170693 | 0.89 | GRM2 (0.44) | GRM2 | |
| SCHEMBL591179 | 0.89 | GRM2 (0.44) | GRM2 | |
| SCHEMBL3334010 | 0.89 | GRM2 (0.44) | GRM2 | |
| SCHEMBL633071 | 0.89 | HTT (0.41) | F10HTTCALML3GAAALDH1A1 | |
| SCHEMBL592187 | 0.89 | MAOA (0.51) | HTTCALML3GAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146987-B1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8916573-B2 | Quinazoline-2,4-dione derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-12-23 | — | — | US | disclosed |
| US-20140171425-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-06-19 | — | — | US | disclosed |
| EP-2254887-B9 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8349826-B2 | Oxazolidinone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-01-08 | — | — | US | disclosed |
| EP-2254887-B1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-19 | — | — | EP | disclosed |
| EP-2346862-B1 | 2-BENZOTHIOPHENYL-AND 2-NAPHTHYL-0XAZ0LIDIN0NES AND THEIR AZAISOSTERE ANALOGUES AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-8114867-B2 | Oxazolidinone antibiotic derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20110195949-A1 | 2-BENZOTHIOPHENYL- AND 2-NAPHTHYL-OXAZOLIDINONES AND THEIR AZAISOSTERE ANALOGUES AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-11 | — | — | US | disclosed |
| US-20100331308-A1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-30 | — | — | US | disclosed |
| EP-2254887-A1 | OXAZOLIDINONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20100137290-A1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-03 | — | — | US | disclosed |
| EP-2146987-A2 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-01-27 | — | — | EP | disclosed |
| WO-2009104159-A1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-27 | — | — | WO | disclosed |
| WO-2008126024-A2 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137290-A1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | OXA1L, XDH, CCNY | F10 1405/4885HTT 3101/4885CALML3 4483/4885 |
| US-20100331308-A1 | OXAZOLIDINONE DERIVATIVES | OXA1L, UQCRB, O60361 | F10 640/4885HTT 4236/4885CALML3 4790/4885 |
| US-20110195949-A1 | 2-BENZOTHIOPHENYL- AND 2-NAPHTHYL-OXAZOLIDINONES AND THEIR AZAISOSTERE ANALOGUES AS ANTIBACTERIAL AGENTS | UQCRB, XDH, TOP2B | F10 1815/4885HTT 4353/4885CALML3 4571/4885 |
| US-20140171425-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES | NQO2, H1-3, H1-0 | F10 2188/4885HTT 2518/4885CALML3 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.